You are here

RSV

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.

...

 

 

 

 

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to RSV
howdy folks
Page loaded in 0.585 seconds.